Samsung Biologics to launch $1.8 billion all cash bid for PolyPeptide
20/07/2026 24:09
Samsung Biologics to launch $1.8 billion all cash bid for PolyPeptide July 20 (Reuters) - Drugmaker Samsung BioLogics 207940.KS will launch an offer to buy all shares of Swiss contract drugmaker PolyPeptide PPGN.S for 44.31 Swiss francs ($54.81) per share, giving the firm an implied equity value of 1.46 billion Swiss francs ($1.81 billion), the companies said.
($1 = 0.8084 Swiss francs)
(Reporting by Mihika Sharma in Bengaluru; Editing by Christian Schmollinger)
Recent news on SAMSUNG BIOLOGICS
See all newsSouth Korean shares log 6-month closing low as chipmakers fall on profit-taking
South Korean shares fall on profit taking; BOK in focus
South Korean shares post biggest gain in 6 weeks as chipmakers rebound
South Korean shares fall nearly 3% as AI concerns hit chipmakers
South Korean shares start week lower on AI worries